FDA Grants Priority Review to Capmatinib for Non-Small Cell Lung Cancer - Cancer Network

1. FDA Grants Priority Review to Capmatinib for Non-Small Cell Lung Cancer  Cancer Network
2. FDA grants capmatinib priority review for non-small cell lung cancer subset  Healio
3. Novartis bags FDA priority review in tight lung cancer race against Merck KGaA  FiercePharma
4. Novartis lung cancer drug gets priority U.S. review  Reuters
5. Potential Lung Cancer Drug from Incyte and Novartis to Get a Priority Review from FDA  Motley Fool
6. View full coverage on Google News